- Home
- THAR vs AURE Comparison
THAR vs AURE Comparison
Compare THAR & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- AURE
- Stock Information
- Founded
- THAR 2017
- AURE 2018
- Country
- THAR United States
- AURE Hong Kong
- Employees
- THAR N/A
- AURE N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- AURE Finance: Consumer Services
- Sector
- THAR Health Care
- AURE Finance
- Exchange
- THAR Nasdaq
- AURE Nasdaq
- Market Cap
- THAR 22.8M
- AURE 19.4M
- IPO Year
- THAR 2022
- AURE N/A
- Fundamental
- Price
- THAR $3.31
- AURE $0.41
- Analyst Decision
- THAR Strong Buy
- AURE
- Analyst Count
- THAR 1
- AURE 0
- Target Price
- THAR $17.00
- AURE N/A
- AVG Volume (30 Days)
- THAR 2.6M
- AURE 3.1M
- Earning Date
- THAR 11-07-2025
- AURE 02-13-2026
- Dividend Yield
- THAR N/A
- AURE N/A
- EPS Growth
- THAR N/A
- AURE N/A
- EPS
- THAR N/A
- AURE N/A
- Revenue
- THAR N/A
- AURE $142,570.00
- Revenue This Year
- THAR N/A
- AURE N/A
- Revenue Next Year
- THAR N/A
- AURE N/A
- P/E Ratio
- THAR N/A
- AURE N/A
- Revenue Growth
- THAR N/A
- AURE N/A
- 52 Week Low
- THAR $0.95
- AURE $0.31
- 52 Week High
- THAR $9.08
- AURE $2.70
- Technical
- Relative Strength Index (RSI)
- THAR 56.35
- AURE N/A
- Support Level
- THAR $2.85
- AURE N/A
- Resistance Level
- THAR $6.89
- AURE N/A
- Average True Range (ATR)
- THAR 0.49
- AURE 0.00
- MACD
- THAR 0.04
- AURE 0.00
- Stochastic Oscillator
- THAR 14.85
- AURE 0.00
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.